ATLANTA & LONDON--(BUSINESS WIRE)--Sciele Pharma, Inc.: Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Holdings PLC (“Plethora” – AIM:PLE), the specialist developer of products for the treatment and management of urological disorders, today announced the final analysis of its European Phase III double-blind placebo-controlled study of PSD502 for the treatment of premature ejaculation (‘PE’). PSD502 has met not only its three co-primary endpoints of Intravaginal Ejaculation Latency Time (‘IELT’) and Index of Premature Ejaculation (‘IPE’; Ejaculatory Control and Sexual Satisfaction domains), but also all secondary endpoints.
